Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2006-01-17
2006-01-17
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
C514S002600, C514S008100, C530S350000
Reexamination Certificate
active
06986894
ABSTRACT:
The present invention related to a method and therapeutic composition for the treatment of coagulation disorders comprising administration of a lipoprotein associated coagulation inhibitor.
REFERENCES:
patent: 4416812 (1983-11-01), Becker
patent: 4470968 (1984-09-01), Mitra et al.
patent: 4473553 (1984-09-01), Zuffi et al.
patent: 4966852 (1990-10-01), Wun et al.
patent: 5017556 (1991-05-01), O'Brien et al.
patent: 5106833 (1992-04-01), Broze et al.
patent: 5110730 (1992-05-01), Edgington et al.
patent: 5589173 (1996-12-01), O'Brien et al.
patent: 266993 (1988-05-01), None
Bach et al.Abstracts of the 59th Scientific Sessions(oral presentation, Annual Convention of the American Heart Assn.) (Nov. 19, 1986).
Bach et al., “Factor VII Binding to Tissue Factor in Reconstituted Phospholipid Vesicles: Induction of Cooperativity by Phosphatidylserine”Biochemistry25(14):4007-4020 (1986).
Bach et al., “Purification and Characterization of Bovine Tissue Factor”Journal of Biological Chemistry256(16):8324-8331 (1981).
Baldus et al., “Successful recanalization of experimentally occluded coronary arteries in anesthetised dogs and recombinant single-chain tissue-type plasminogen activator (sct-PA)”Fibrinolysis1(1):23-28 (1987).
Beck et al.Hematology, MIT Press pps. 381-382 & 436-437 (1981).
Bjorklid et al., “Purification and Some Properties of the Protein Component of Tissue Thromboplastin from Human Brain”Biochemical Journal165(1):89-96 (1977).
Bjorklid et al., “The Protein Component of Human Brain Thromboplastin”Biochemical and Biophysical Research Communications55(3):969-976 (1973).
Blakeslee et al., “Scientists find Long-Sought Key to How Blood Clots”New York Times(Jul. 7, 1987).
Bom et al., “Application of Factor VII-Sepharose Affinity Chromatography in the Purification of Human Tissue Factor Apoprotein”Thrombosis Research42:635-643 (1986).
Brommer et al., “Survival of fibrinogen degradation products in the circulation after thrombolytic therapy for acute myocardial infarction”Fibrolysis1(3):149-153 (1987).
Broze et al., “Isolation of the Tissue Factor Inhibitor Produced by HepG2 Hepatoma Cells”Proc. Natl. Acad. Sci. USA84:1886-1890 (Apr. 1987).
Broze, Jr. et al., “The Lipoprotein-Associated Coagulation Inhibitor That Inhibits the Factor VII-Tissue Factor Complex Also Inhibits Factor Xa: Insight Into Its Possible Mechanism of Action”Blood71(2):335-343 (Feb. 1988).
Broze, Jr., et al., “Purification of Human Brain Tissue Factor”Journal of Biological Chemistry260(20):10917-10920 (1985).
Callas et al., “Comparative Pharmacology of Site Directed Antithrombin Agents. Implication in Drug Development”Thrombosis and Haemostasis74(1):473-481 (1995).
Carlsen et al., “Intravenous Injections of Tissue Thromboplastin and Phospholipase C in Sheep”Thrombosis Haemostasis48(3):315-319 (1982).
Carson et al., “An inhibitory monoclonal antibody against human tissue factor”Blood70(2):490-493 (1987).
Carson et al., “Lipid activation of coagulation factor III apoprotein (tissue factor)—reconstitution of the protein-membrane complex”Chemical Abstracts94(244):13337f (1981).
Carson et al., “Monoclonal Antibodies Aginst Bovine Tissue Factor, Which Block Interaction with Factor VIIa”Blood66(1):152-156 (1985).
Carson et al., “Plasma High Density Lipoproteins Inhibit the Activation of Coagulation Factor X by Factor VIIa and Tissue Factor”FEBS Letters132(1):37-40 (1981).
Carson et al., “Tissue Factor Gene Localized to Human Chromosome 1 (1pter-1p21)”Science229:991-993 (1985).
Carson, S.D., “Tissue Factor-Initiated Blood Coagulation”Progress in Clinical Pathology, Stefanini et al., Grune & Stratton vol. 9:1-14 (1984).
Collen et al., “Thrombolytic Therapy”Annu. Rev. Med. 39:405-423 (Apr. 1988).
Dennis and Lazarus, “Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa; I. Potent Inhibitors Selected from Libraries by Phage Display”Journal of Biological Chemistry269(35):22129-22136 (1994).
Dorland's Illustrated Medical Dictionary, 26th edition, W.B. Saunders Company pps. 281-282, 1071 (1981).
Edgington et al., “Molecular Cloning of Human Tissue Factor cDNA”Thrombosis and Haemostasis(Abstract No. 941) 58(1):258 (Jan. 1987).
Esnouf, “Extrinsic Activation of Prothrombin”Human Blood Coagulation, Haemostasis and Thrombosispps. 55-65 (1976).
Ewan et al., “Production and Characterization of a Monoclonal Antibody (A1-3) That Binds Selectively to Activated Monocytes and Inhibits Monocyte Procoagulant Activity”J. Immunol. 136(7):2408-2415 (1986).
Falk, “Plaque Rupture with Severe Pre-existing Stenosis Precipitating Coronary Thrombosis”Br. Heart J. 50:127-134 (1983).
Fisher et al., “Cloning and Expression of Human Tissue Factor cDNA”Thrombosis Research48(1):89-99 (1987).
Freyssinet et al., “Coextraction of Thrombomodulin and Tissue Factor from Human Placenta: Effects of Concanavalin A and Phospholid Environment on Activity”Thrombosis and Haemostasis55(1):112-118 (1986).
Giercksky et al., “The Effect of Intravenous Injection of Purified Human Tissue Thromboplastin in Rats”Scand. J. Haematol. 16(4):300-310 (Apr. 1976).
Gitel et al., “The Antithrombotic Effects of Warfarin and Heparin Following Infusions of Tissue Thromboplastin in Rabbits: Clinical Implications”J. of Laboratory Clinical Medicine94(3):481-488 (1979).
Gollub et al., “Thromboplastinase-an Experimental Anti-thrombotic”Thromb. Diath. Haemorh. 7:470-479 (1962).
Gonmori et al., “The Role of Tissue Thromboplastin in the Development of DIC Accompanying Neoplastic Diseases”Biblio. Haematol. 49:23-39 (1983).
Guha et al., “Affinity purification of human tissue factor: Interaction of factor VII and tissue factor in detergent micelles”Proc. Natl. Acad. Sci. USA83:299-302 (1986).
Harker, “Role of Platelets and Thrombosis in Mechanisms of Acute Occlusion and Restenosis After Angioplasty”The American Journal of Cardiology60:20B-28B (Jul. 1987).
Haskel et al., “Prevention of Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein-Associated Coagulation Inhibitor”Circulation84(2):821-827 (1991).
Haskel et al., “Prevention of Reoccluding Platelet-Rich Thrombi in Canine Femoral Arteries With a Novel Peptide Antagonist of Platelet Glycoprotein IIb/IIIa Receptors”Circulation80(6):1775-1782 (1989).
Jang et al., “Antithrombotic Effect of a Monoclonal Antibody Against Tissue Factor in a Rabbit Model of Platelet-Mediated Arterial Thrombosis”Arteriosclerosis and Thrombosis12(8):948-954 (Aug. 1992).
Johns et al., “Prevention of Coronary Artery Reocclusion and Reduction in Late Coronary Artery Stenosis After Thrombolytic Therapy in Patients With Acute Myocardial Infarction”Circulation78(3):546-556 (1988).
Kelley et al., “Analysis of the Factor VIIa Binding Site on Human Tissue Factor: Effects of Tissue Factor Mutations on the Kinetics and Thermodynamics of Binding”Biochemistry34(33):10383-10392 (1995).
Kittler et al., “Identification of a cDNA Clone for Bovine Tissue Factor”76th Ann. Mtg. of the American Society of Biol. Chemists, Wash., D.C., Fed. Proc. (Abstract 927) 45(6):1639 (Jun. 1986).
Konigsberg et al., “Molecular Cloning of the cDNA for Human Tissue Factor”Cell52:639-640 (1988).
Kurosawa et al., “Urinary Procoagulant Behaves as Tissue Factor by Promoting Factor VIIa-Catalyzed Activation of Factor X”Thrombosis Research33:595-606 (1984).
Lewis et al., “Effects of intrvaneous tissue thomboplastin in dogs: Development of an anticoagulant”J. of Laboratory Clinical Medicine60(2):261-273 (1962).
Light, A., “Protein Solubility, Protein Modifications and Protein Folding”Biotech
O'Brien Donogh P.
Vehar Gordon A.
Gambel Phillip
Genentech Inc.
Shin Elinor K.
LandOfFree
Methods for the treatment of coagulation disorders with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of coagulation disorders with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of coagulation disorders with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3561574